Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) has priced an underwritten public offering of 5,251,239 shares at $10.00 per share and pre-funded warrants for 9,748,761 shares at $9.99 each. The total gross proceeds are estimated at $150 million, before expenses. The offering is set to close on April 29, 2022. Proceeds will fund the development of vimseltinib for tenosynovial giant cell tumor patients, DCC-3116 combination studies, and the pan-RAF program, along with general working capital needs. J.P. Morgan and Jefferies are the joint book-running managers.

Positive

• Deciphera aims to raise approximately $150 million from the offering to support ongoing and future clinical trials.
• Funding will bolster the development of vimseltinib in a pivotal Phase 3 study and DCC-3116 studies across various tumor types.

Negative

• The offering could lead to shareholder dilution if the underwriters exercise their option for an additional 2,250,000 shares.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 5,251,239 shares of its common stock at a public offering price of $10.00 per share. In addition, in lieu of common stock to certain investors, Deciphera is offering pre-funded warrants to purchase 9,748,761 shares of its common stock at a purchase price of $9.99 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.01 exercise price per share of each pre-funded warrant. The aggregate gross proceeds to Deciphera from this offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Deciphera has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock at the public offering price per share of the common stock, less underwriting discounts and commissions. The offering is expected to close on April 29, 2022, subject to the satisfaction of customary closing conditions. All of the shares of common stock and pre-funded warrants are being offered by Deciphera.

Deciphera intends to use the net proceeds from the offering to continue to fund the development of vimseltinib including in its pivotal Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway, additional clinical trials as well as clinical research outsourcing and manufacturing of clinical trial material and pre-commercial and medical affairs capabilities related to vimseltinib; to fund the development of DCC-3116 including multiple Phase 1b combination studies and potential Phase 2 expansion combination cohorts in multiple tumor types as well as clinical research outsourcing and manufacturing of clinical trial material; to fund the research and development of Deciphera’s pan-RAF program and other new research activities for potential drug candidates from its proprietary kinase switch control inhibitor platform; and the remainder for working capital purposes, including general operating expenses.

J.P. Morgan and Jefferies are acting as joint book-running managers for the offering.

The securities described above are being offered by Deciphera pursuant to a shelf registration statement on Form S-3 (No. 333-236389) that was declared effective by the Securities and Exchange Commission (SEC) on March 10, 2022. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on April 26, 2022, and is available on the SEC’s website located at www.sec.gov. A copy of the final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements related to the timing and completion of the proposed offering and the anticipated use of proceeds from the proposed offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. These risks and uncertainties include fluctuations in Deciphera’s stock price, changes in market conditions, satisfaction of customary closing conditions related to the public offering, and other risks identified in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2021, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006379/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

David.Rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

What is the pricing of the public offering by DCPH?

Deciphera Pharmaceuticals has priced its public offering at $10.00 per share for 5,251,239 shares.

How much gross proceeds is Deciphera expecting from the public offering?

The aggregate gross proceeds are expected to be approximately $150 million before expenses.

What will Deciphera use the proceeds from the offering for?

The proceeds will fund the development of vimseltinib, DCC-3116, and the pan-RAF program, as well as general working capital.

When is the closing date for the Deciphera public offering?

The offering is expected to close on April 29, 2022.

Who are the joint book-running managers for DCPH's offering?

J.P. Morgan and Jefferies are acting as joint book-running managers for the offering.